viewBiocept Inc

Biocept reports record 3Q revenue of $1.5 million as Target Selector testing ramps up

The San Diego-based molecular diagnostics firm reported total revenue of $1.5 million, a 101% increase from the year-ago quarter

lab testing
The higher revenue figures were largely thanks to a 66% increase in the number of billable commercial samples

Biocept Inc (NASDAQ:BIOC) reported record third-quarter revenue driven by commercial testing of its liquid biopsy technology Target Selector, according to results released on Wednesday afternoon.

The San Diego-based molecular diagnostics firm reported total 3Q revenue of $1.5 million, a 101% increase over 2018 figures and up 28% from the previous quarter.

Revenues for the quarter included $1.4 million in commercial test revenue, $40,000 in development services test revenue and $60,000 in revenue for Target Selector RUO kits, which were commercially launched in early 2019, and CEE-Sure blood collection tubes. 

READ: Biocept's CEE-Sure Blood Collection Tubes and Shipping Kits now available in Europe

The higher revenue figures were largely thanks to a 66% increase in the number of billable commercial samples, the company told investors.

Biocept CEO Michael Nall hailed the strong results, telling investors that its focus on continued growth in commercial volume and improvement in gross margin percent through operational efficiencies is paying off.

"Testing for lung cancer continued to be among the largest contributors to commercial volume due to the difficulties in securing lung tissue samples from this patient population," Nall said in a statement. 

The CEO told shareholders that the firm is gaining traction in the uro-oncology market where its blood-based testing is used by urologists to monitor patients with rising prostate-specific antigen (PSA) levels, as well as in the post-surgery setting to identify patients at risk for cancer recurrence. 

“We are seeing increasing reorders from the physicians and practices who began using our Target Selector products earlier this year, while establishing relationships with additional urologists and urology practice groups during the third quarter,” Nall said.

Target Selector testing for breast cancer was also a key contributor to commercial volume growth during the quarter, according to Nall:

“Clinicians treating patients with breast cancer are utilizing our blood-based assays for initial profiling of biomarkers to ensure that critical biomarkers are not missed with the original tissue biopsy as well as to re-profile patients who have cancer recurrence in order to determine the most appropriate treatment plan for each patient.”

Research and development expenses for the firm came in at $1.2 million as it continued to develop and validate new assays.

The firm posted a net loss of $5.7 million or $0.25 per share compared to $6.7 million or $2.42 per share over the year-ago period.

Shares of Biocept gained 3.1% after the bell at $0.68.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Biocept Inc

Price: 0.31 USD

Market: NASDAQ
Market Cap: $13.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...



Biocept pursuing new strategy with a physician association using its liquid...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the liquid biopsy test provider has struck up an agreement with an undisclosed independent physician association in California to provide liquid biopsy testing services to its physicians and patients. Nall says this is the first value-based...

2 weeks, 1 day ago

2 min read